(OGN) Organon - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US68622V1061

Contraception, Fertility, Biosimilars, Cardiometabolic, Respiratory, Dermatology

Pharmaceuticals
Market Cap in USD: 2,093m

IPO / Inception: 2021-06-02
12m vs SPY: -53.4%

EPS (Earnings per Share)

EPS CAGR: -7.81%
EPS Trend: -56.3%

Last SUE: 0.64
Qual. Beats: 0

Revenue

Rev. CAGR: -0.02%
Rev. Trend: 20.2%

Last SUE: 0.72
Qual. Beats: 0

Dividends

Dividend Yield	2.58%
Yield on Cost 5y	1.25%
Yield CAGR 5y	-11.73%
Payout Consistency	86.5%
Payout Ratio	8.7%

Risk via 5d forecast
Volatility	43.2%
Value at Risk 5%th	64.2%
Relative Tail Risk	-9.61%

Reward TTM
Sharpe Ratio	-0.69
Alpha	-62.83
CAGR/Max DD	-0.42

Character TTM
Hurst Exponent	0.425
Beta	0.943
Beta Downside	0.978

Drawdowns 3y
Max DD	77.12%
Mean DD	44.79%
Median DD	43.89%

Description: OGN Organon January 12, 2026

Organon & Co. (NYSE: OGN) is a U.S.–based, globally diversified pharmaceutical company that markets prescription drugs and medical devices across North America, Europe, Asia-Pacific, Latin America, the Middle East, Russia, and Africa. Founded in 1923 and headquartered in Jersey City, New Jersey, the firm operates under the GICS sub-industry “Pharmaceuticals” and generates the majority of its $2.3 billion FY-2023 revenue from the United States, where it sells to wholesalers, hospitals, PBMs, and government programs.

The core of Organon’s growth engine is its women’s-health portfolio, which includes long-acting reversible contraceptives (Nexplanon), the monthly NuvaRing, daily oral pills (Cerazette, Marvelon, Mercilon), and fertility-assisted-reproduction agents such as Follistim AQ, Elonva, and Ganirelix. The global women’s-health market is expanding at a ~6 % CAGR, driven by rising demand for convenient birth-control options and increased access to fertility treatments in emerging economies-trends that directly support Organon’s product mix.

Beyond women’s health, Organon has built a sizable biosimilars franchise (Brenzys, Renflexis, Hadlima) and oncology follow-on products (Ontruzant, Aybintio). The company also markets cholesterol-lowering agents (Zetia, Vytorin, Zocor), antihypertensives (Cozaar, Hyzaar), respiratory therapies (Singulair, Dulera, Asmanex, Nasonex), dermatology, bone-health, and non-opioid pain-management drugs. In FY-2023, biosimilars contributed roughly 12 % of total sales, and Organon’s pipeline includes an adalimumab biosimilar slated for 2025 launch-positioning it to capture part of the $30 billion U.S. biosimilar market that is expected to grow at double-digit rates as patents expire.

Operating in a sector where Medicare Part D pricing reforms and generic competition compress margins, Organon’s 2023 operating margin of 13 % reflects disciplined cost control and a focus on higher-margin specialty brands. For a deeper quantitative view of Organon’s valuation metrics, a quick look at ValueRay’s analyst dashboard can be useful.

Piotroski VR‑10 (Strict, 0-10) 3.0

Net Income (501.0m TTM) > 0 and > 6% of Revenue (6% = 378.1m TTM)

FCFTA 0.04 (>2.0%) and ΔFCFTA -1.01pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 32.07% (prev 30.68%; Δ 1.40pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.07 (>3.0%) and CFO 949.0m > Net Income 501.0m (YES >=105%, WARN >=100%)

Net Debt (8.16b) to EBITDA (1.57b) ratio: 5.18 <= 3.0 (WARN <= 3.5)

Current Ratio 1.75 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (260.7m) change vs 12m ago 0.34% (target <= -2.0% for YES)

Gross Margin 55.04% (prev 58.26%; Δ -3.22pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 47.91% (prev 50.26%; Δ -2.35pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 2.37 (EBITDA TTM 1.57b / Interest Expense TTM 516.0m) >= 6 (WARN >= 3)

Altman Z'' 1.98

(A) 0.15 = (Total Current Assets 4.70b - Total Current Liabilities 2.68b) / Total Assets 13.55b

(B) 0.10 = Retained Earnings (Balance) 1.32b / Total Assets 13.55b

(D) 0.06 = Book Value of Equity 747.0m / Total Liabilities 12.65b

Total Rating: 1.98 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 56.51

1. Piotroski 3.0pt

2. FCF Yield 5.52%

3. FCF Margin 8.98%

4. Debt/Equity 9.74

5. Debt/Ebitda 5.18

6. ROIC - WACC (= 5.84)%

7. RoE 75.54%

8. Rev. Trend 20.18%

9. EPS Trend -56.26%

What is the price of OGN shares?

As of January 15, 2026, the stock is trading at USD 8.61 with a total of 3,362,745 shares traded.
Over the past week, the price has changed by +5.13%, over one month by +22.65%, over three months by -9.69% and over the past year by -44.14%.

Is OGN a buy, sell or hold?

Organon has received a consensus analysts rating of 3.00. Therefor, it is recommend to hold OGN.

Strong Buy: 0
Buy: 2
Hold: 3
Sell: 2
Strong Sell: 0

What are the forecasts/targets for the OGN price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	9.4	8.7%
Analysts Target Price	9.4	8.7%
ValueRay Target Price	6.5	-25%

OGN Fundamental Data Overview January 13, 2026

P/E Trailing = 4.2147
P/E Forward = 5.0302
P/S = 0.3321
P/B = 2.31
Revenue TTM = 6.30b USD
EBIT TTM = 1.22b USD
EBITDA TTM = 1.57b USD
Long Term Debt = 8.78b USD (from longTermDebt, last quarter)
Short Term Debt = 45.0m USD (from shortTermDebt, last quarter)
Debt = 8.83b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 8.16b USD (from netDebt column, last quarter)
Enterprise Value = 10.25b USD (2.09b + Debt 8.83b - CCE 672.0m)
Interest Coverage Ratio = 2.37 (Ebit TTM 1.22b / Interest Expense TTM 516.0m)
EV/FCF = 18.11x (Enterprise Value 10.25b / FCF TTM 566.0m)
FCF Yield = 5.52% (FCF TTM 566.0m / Enterprise Value 10.25b)
FCF Margin = 8.98% (FCF TTM 566.0m / Revenue TTM 6.30b)
Net Margin = 7.95% (Net Income TTM 501.0m / Revenue TTM 6.30b)
Gross Margin = 55.04% ((Revenue TTM 6.30b - Cost of Revenue TTM 2.83b) / Revenue TTM)
Gross Margin QoQ = 53.50% (prev 54.83%)
Tobins Q-Ratio = 0.76 (Enterprise Value 10.25b / Total Assets 13.55b)
Interest Expense / Debt = 1.45% (Interest Expense 128.0m / Debt 8.83b)
Taxrate = 34.16% (83.0m / 243.0m)
NOPAT = 804.0m (EBIT 1.22b * (1 - 34.16%))
Current Ratio = 1.75 (Total Current Assets 4.70b / Total Current Liabilities 2.68b)
Debt / Equity = 9.74 (Debt 8.83b / totalStockholderEquity, last quarter 906.0m)
Debt / EBITDA = 5.18 (Net Debt 8.16b / EBITDA 1.57b)
Debt / FCF = 14.41 (Net Debt 8.16b / FCF TTM 566.0m)
Total Stockholder Equity = 663.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.81% (Net Income 501.0m / Total Assets 13.55b)
RoE = 75.54% (Net Income TTM 501.0m / Total Stockholder Equity 663.2m)
RoCE = 12.93% (EBIT 1.22b / Capital Employed (Equity 663.2m + L.T.Debt 8.78b))
RoIC = 8.42% (NOPAT 804.0m / Invested Capital 9.55b)
WACC = 2.57% (E(2.09b)/V(10.92b) * Re(9.39%) + D(8.83b)/V(10.92b) * Rd(1.45%) * (1-Tc(0.34)))
Discount Rate = 9.39% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.79%
[DCF Debug] Terminal Value 86.76% ; FCFF base≈604.0m ; Y1≈630.9m ; Y5≈728.8m
Fair Price DCF = 51.84 (EV 21.63b - Net Debt 8.16b = Equity 13.48b / Shares 260.0m; r=5.90% [WACC]; 5y FCF grow 4.76% → 2.90% )
EPS Correlation: -56.26 | EPS CAGR: -7.81% | SUE: 0.64 | # QB: 0
Revenue Correlation: 20.18 | Revenue CAGR: -0.02% | SUE: 0.72 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.01 | Chg30d=+0.031 | Revisions Net=+1 | Analysts=3
EPS next Year (2026-12-31): EPS=3.96 | Chg30d=-0.084 | Revisions Net=-3 | Growth EPS=+4.9% | Growth Revenue=-0.9%

Additional Sources for OGN Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle